

Leviticus Cardio Announces Successful First in Human Case for its Paradigm-shifting Wireless Heart Pump System

New hope for severe heart failure patients is unveiled.

Misgav, Israel – 11 February 2019 – The Trendlines Group (The Trendlines Group Ltd. (“Trendlines”) (SGX: 42T; OTCQX: TRNLY), announced today that its portfolio company Leviticus Cardio Ltd. (“Leviticus”) together with Jarvik Heart Inc. unveiled their ground-breaking wireless heart pump system to the public on 6 February 2019. Following years of development and animal testing, [Leviticus announced the first successful implant](#) of a Fully Implanted Ventricular Assist Device (“FIVAD”) in a human, which took place in December 2018 at the National Research Center for Cardiac Surgery in Astana, Kazakhstan. The patient was in the audience during a press conference, after being discharged from hospital and returned back home to a normal life.

At the [press conference](#), top heart failure experts from around the world announced the successful implantation of FIVAD into a human. Prior to the conference, [an article about the FIVAD implantation](#) was published by the prestigious Journal for Heart and Lung Transplantation (JHLT). Among those who participated in the press conference was Professor Mandeep Mehra – Professor of Medicine - Harvard Medical School, and Editor-in-Chief of The Journal of Heart and Lung Transplantation.

“We, the medical community, cardiologists, cardiac surgeons, VAD coordinators and the patients have wanted this for decades,” according to another participant at the conference, [Professor Nir Uriel](#), Director of the University of Chicago Medical Center for Heart Failure, Transplant and Mechanical Circulatory Support.

An alternative to the thousands of patients who are candidates for heart transplantation each year, is the ventricular assist device (VAD), an implanted mechanical circulatory pump that is increasingly being used to support patients with severe heart failure. These VADs need to continuously be connected to a power source requiring patients to have a wire (drive line) coming out of their bodies. Patients are highly vulnerable to device-related infections and suffer a major reduction in quality of life: two issues which represent the most important challenges to extended VAD use.

[Leviticus](#), a medical technology company headquartered in Israel began its technology development in the Trendlines’ incubator. Leviticus has successfully developed the FIVAD, a fully implanted VAD system, powered wirelessly using both internal and external components which allows patients to walk around without any physical impediments for up to 8 hours a day. FIVAD incorporates a heart pump produced by [Jarvik Heart Inc](#), an established manufacturer of ventricular assist devices.

Trendlines' Chairman and CEO, Steve Rhodes commented, "Leviticus has developed a game-changing product in the VAD market. We look forward to their progress in making the FIVAD the gold standard for treatment that truly brings new hope to patients who suffer from severe heart failure. We are extremely proud of the Leviticus team and delighted to be a part of their journey."

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

About Leviticus Cardio Ltd.

Founded in 2008, Leviticus Cardio (Leviticus-cardio.com) is a medical device company dedicated to improving the clinical outcome for patients with an implanted left ventricular assist device (LVAD) for the treatment of impaired cardiac function. The Company has received funding from The Trendlines Group, Israel's foremost seed- and early-stage investment group, a consortium of acclaimed cardiovascular physicians, private investors and Israel's Innovation Authority (previously, the Office of the Chief Scientist of the Ministry of Economy).

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore and China:

Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy,

completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

GENERAL ANNOUNCEMENT::PRESS RELEASE - LEVITICUS CARDIO ANNOUNCES SUCCESSFUL FIRST IN HUMAN CASE

Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date &Time of Broadcast

11-Feb-2019 17:12:54

Status

New

Announcement Sub Title

Press Release - Leviticus Cardio Announces Successful First in Human Case

Announcement Reference

SG190211OTHRHWOW

Submitted By (Co/ Ind. Name)

Haim Brosh

Designation

Joint Company Secretary